Definium Therapeutics (NASDAQ:DFTX) Insider Mark Sullivan Sells 13,008 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Definium Therapeutics Price Performance

Shares of DFTX stock traded up $0.16 during mid-day trading on Friday, reaching $44.95. The company’s stock had a trading volume of 12,203,314 shares, compared to its average volume of 2,289,586. Definium Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.01. The company has a market cap of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The firm’s 50-day moving average is $24.13 and its two-hundred day moving average is $19.18.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, research analysts predict that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Definium Therapeutics during the 3rd quarter worth approximately $107,000. Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics during the 4th quarter valued at $117,000. Finally, Caxton Associates LLP acquired a new stake in Definium Therapeutics during the 3rd quarter valued at $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analyst Upgrades and Downgrades

DFTX has been the topic of a number of recent research reports. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. Stifel Nicolaus set a $30.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 16th. HC Wainwright boosted their price target on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. JonesTrading upped their price target on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $47.08.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.